Exact Sciences stock drops as cancer test disappoints

[riky]

Exact Sciences stock drops as cancer test disappoints

By Esha Dey and Susan Kelly (Reuters) - Exact Sciences Corp said its molecular screening test for colorectal cancer met its goals in a large late-stage study, detecting the disease in more than 90 percent of patients, but its shares plummeted as much as 30 percent on Thursday as the results were not as robust as some were expecting. Exact's test, which identifies abnormal DNA in cells shed in a patient's stool, detected 92 percent of colorectal cancers and 42 percent of pre-cancerous polyps in a large late-stage study. ...

Source: You are not allowed to view links. Register or Login